Meeting
2019 ASCO Annual Meeting
Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.
Authors
Ronan Flippot
Dana-Farber Cancer Institute, Boston, MA
Ronan Flippot , Bradley Alexander McGregor , Abdallah Flaifel , Kathryn P. Gray , Sabina Signoretti , John A. Steinharter , Eliezer Mendel Van Allen , Meghara K. Walsh , Katy Gundy , Xiao X. Wei , Lauren Christine Harshman , Ulka N. Vaishampayan , Toni K. Choueiri , Rana R. McKay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02724878
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4583)
DOI
10.1200/JCO.2019.37.15_suppl.4583
Abstract #
4583
Poster Bd #
409
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.
First Author: Ronan Flippot
Poster
2019 Genitourinary Cancers Symposium
Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).
First Author: Rana R. McKay
Poster
2014 ASCO Annual Meeting
PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
First Author: Andre Poisl Fay
Poster
2014 Genitourinary Cancers Symposium
PD-L1 expression in non-clear cell renal cell carcinoma.
First Author: André P Fay